feed,title,long_url,short_url
GN:S:RL,Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers - EurekAlert,https://www.eurekalert.org/news-releases/951941,https://bit.ly/3MW2USq
